BR112014010406A2 - cromatografia de sobrecarga e eluto - Google Patents

cromatografia de sobrecarga e eluto

Info

Publication number
BR112014010406A2
BR112014010406A2 BR112014010406A BR112014010406A BR112014010406A2 BR 112014010406 A2 BR112014010406 A2 BR 112014010406A2 BR 112014010406 A BR112014010406 A BR 112014010406A BR 112014010406 A BR112014010406 A BR 112014010406A BR 112014010406 A2 BR112014010406 A2 BR 112014010406A2
Authority
BR
Brazil
Prior art keywords
overload
elute chromatography
chromatography
elute
polypeptide
Prior art date
Application number
BR112014010406A
Other languages
English (en)
Inventor
Mehta Amit
Nadarajah Deepa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192803&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014010406(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112014010406A2 publication Critical patent/BR112014010406A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/14—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the introduction of the feed to the apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography

Abstract

resumo patente de invenção: "cromatografia de sobrecarga e eluto". a presente invenção refere-se a métodos para purificar um polipeptídeo de uma composição compreendendo o polipeptídeo e pelo menos um contaminante por sobrecarga de um material de cromatografia e eluição do produto.
BR112014010406A 2011-11-02 2012-11-02 cromatografia de sobrecarga e eluto BR112014010406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554898P 2011-11-02 2011-11-02
PCT/US2012/063242 WO2013067301A1 (en) 2011-11-02 2012-11-02 Overload and elute chromatography

Publications (1)

Publication Number Publication Date
BR112014010406A2 true BR112014010406A2 (pt) 2017-04-25

Family

ID=48192803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010406A BR112014010406A2 (pt) 2011-11-02 2012-11-02 cromatografia de sobrecarga e eluto

Country Status (25)

Country Link
US (3) US20140301977A1 (pt)
EP (3) EP3527274A1 (pt)
JP (4) JP6356607B2 (pt)
KR (1) KR20140091721A (pt)
CN (2) CN104023804B (pt)
AU (1) AU2012323995B2 (pt)
BR (1) BR112014010406A2 (pt)
CA (1) CA2854330A1 (pt)
DK (2) DK3257564T3 (pt)
ES (2) ES2637423T5 (pt)
HK (1) HK1201489A1 (pt)
HR (1) HRP20190485T1 (pt)
HU (2) HUE035685T2 (pt)
IL (1) IL232146A0 (pt)
LT (1) LT3257564T (pt)
MX (1) MX2014005330A (pt)
PL (2) PL3257564T3 (pt)
PT (1) PT3257564T (pt)
RS (1) RS58472B1 (pt)
RU (1) RU2014121884A (pt)
SG (1) SG11201402019TA (pt)
SI (2) SI2773438T2 (pt)
TR (1) TR201903707T4 (pt)
WO (1) WO2013067301A1 (pt)
ZA (1) ZA201402932B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535683A (ja) 2010-07-30 2013-09-12 イー・エム・デイー・ミリポア・コーポレイシヨン クロマトグラフィー媒体及び方法
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP6356607B2 (ja) 2011-11-02 2018-07-11 ジェネンテック， インコーポレイテッド オーバーロード／溶出クロマトグラフィー
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2888824C (en) * 2012-10-24 2021-02-02 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes as mobile phase modifier
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN110054661A (zh) 2013-12-12 2019-07-26 Emd密理博公司 使用含丙烯酰胺的过滤器分离蛋白
WO2015086853A1 (en) * 2013-12-13 2015-06-18 Novo Nordisk Health Care Ag Method for thioether conjugation of proteins
KR20150083689A (ko) * 2014-01-10 2015-07-20 삼성전자주식회사 항 c-Met 항체 정제 방법
CN106103465B (zh) 2014-03-10 2021-01-08 吉瑞工厂 使用预清洗步骤的免疫球蛋白纯化
WO2015146487A1 (ja) * 2014-03-24 2015-10-01 日東紡績株式会社 新規カチオン性グラフト重合体を用いた標的物分離濃縮方法
CN106459139A (zh) * 2014-05-28 2017-02-22 新加坡科技研究局 病毒减少方法
SG11201610431WA (en) * 2014-06-25 2017-01-27 Jhl Biotech Inc Methods and reagents for purification of proteins
CN104208719B (zh) * 2014-09-24 2017-05-03 北京天广实生物技术股份有限公司 一种抗体偶联药物的阳离子交换层析纯化方法
JP6665184B2 (ja) * 2014-12-08 2020-03-13 イー・エム・デイー・ミリポア・コーポレイシヨン 混床イオン交換吸着剤
EP3636749B1 (en) * 2015-03-06 2022-04-27 F. Hoffmann-La Roche AG Ultrapurified dsbc and methods of making and using the same
CN106290591B (zh) * 2015-05-14 2019-07-26 上海医药工业研究院 一种庆大霉素C1a的检测方法
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
WO2018035025A1 (en) * 2016-08-15 2018-02-22 Genentech, Inc. Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
GB201702856D0 (en) * 2017-02-22 2017-04-05 Ge Healthcare Bio Sciences Ab Method in continuous chromatography
EP3707250A1 (en) * 2017-11-08 2020-09-16 Blue Sky Vaccines GmbH So3 chromatography for use in a method for virus purification
CA3104392A1 (en) * 2018-07-04 2020-01-09 Probiogen Ag Method for purifying an enveloped virus
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CN111351876A (zh) * 2020-04-01 2020-06-30 上海中科新生命生物科技有限公司 一种抗体药中宿主细胞蛋白半绝对定量检测方法
US11379651B1 (en) * 2020-07-06 2022-07-05 Turtl Surf & Immerse Limited Methods and systems for interactive content creation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2106612C (en) * 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
KR20050084473A (ko) * 1996-09-13 2005-08-26 트랜스케리오틱 쎄러피스, 인코포레이티드 α-갈락토시다아제 Ａ 결핍을 치료하는 방법
EP1864999B1 (en) * 1996-11-27 2009-03-18 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
ATE321066T1 (de) * 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2447832C (en) 2000-12-22 2012-09-25 Jamshid Tanha Phage display libraries of human vh fragments
BR0206852A (pt) * 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20070261962A1 (en) * 2002-04-02 2007-11-15 Ryszard Gajek Separation Systems with Charge Mosaic Membrane
WO2004035180A1 (ja) * 2002-10-18 2004-04-29 Asahi Kasei Pharma Corporation 親水性微多孔膜
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
MX2007011129A (es) * 2005-03-11 2007-11-06 Wyeth Corp Un metodo de cromatografia de particion debil.
US8153009B2 (en) 2005-04-22 2012-04-10 Waters Technologies Corporation Apparatus and methods for mass-spectrometric directed purification of biopolymers
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
BRPI0716382B8 (pt) * 2006-08-28 2021-05-25 Ares Trading Sa método para reduzir o teor de porções de fc livres em um fluido compreendendo uma proteína contendo fc, e uso de cromatografia de troca catiônica
RU2009148891A (ru) 2007-06-01 2011-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Очистка иммуноглобулина
DE102009005479A1 (de) * 2009-01-21 2010-07-22 Sartorius Stedim Biotech Gmbh Vorrichtung und Verfahren für die Stofftrennung
JP5614936B2 (ja) * 2009-02-19 2014-10-29 旭化成ケミカルズ株式会社 アニオン交換基が固定された多孔膜を用いた核酸の精製方法
SG177577A1 (en) * 2009-08-07 2012-03-29 Emd Millipore Corp Methods for purifying a target protein from one or more impurities in a sample
WO2011035282A1 (en) * 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
CN102094034A (zh) * 2009-12-09 2011-06-15 泰州新生源生物医药有限公司 一种重组人Fc融合长效干扰素的纯化工艺
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2640483A1 (en) * 2010-11-15 2013-09-25 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
JP6356607B2 (ja) 2011-11-02 2018-07-11 ジェネンテック， インコーポレイテッド オーバーロード／溶出クロマトグラフィー

Also Published As

Publication number Publication date
ZA201402932B (en) 2016-08-31
JP2020059718A (ja) 2020-04-16
WO2013067301A1 (en) 2013-05-10
CN107163101A (zh) 2017-09-15
JP6356607B2 (ja) 2018-07-11
SG11201402019TA (en) 2014-09-26
EP2773438A4 (en) 2015-06-03
JP7203928B2 (ja) 2023-01-13
EP3257564B1 (en) 2019-01-23
CN104023804A (zh) 2014-09-03
JP2018184405A (ja) 2018-11-22
SI2773438T1 (sl) 2017-10-30
KR20140091721A (ko) 2014-07-22
ES2717536T3 (es) 2019-06-21
PT3257564T (pt) 2019-03-22
NZ624317A (en) 2016-06-24
EP2773438A1 (en) 2014-09-10
DK3257564T3 (en) 2019-04-15
RU2014121884A (ru) 2015-12-10
IL232146A0 (en) 2014-05-28
DK2773438T3 (en) 2017-08-21
PL2773438T3 (pl) 2017-11-30
HRP20190485T1 (hr) 2019-04-19
US20210206836A1 (en) 2021-07-08
HUE035685T2 (en) 2018-05-28
TR201903707T4 (tr) 2019-04-22
CN107163101B (zh) 2021-08-17
EP2773438B1 (en) 2017-06-14
AU2012323995A1 (en) 2013-05-16
CN104023804B (zh) 2017-05-24
ES2637423T3 (es) 2017-10-13
RS58472B1 (sr) 2019-04-30
JP2014532718A (ja) 2014-12-08
JP6979442B2 (ja) 2021-12-15
EP2773438B2 (en) 2021-10-20
CA2854330A1 (en) 2013-05-10
SI3257564T1 (sl) 2019-04-30
AU2012323995B2 (en) 2016-06-09
MX2014005330A (es) 2014-09-08
HK1201489A1 (en) 2015-09-04
DK2773438T4 (da) 2022-01-03
US20140301977A1 (en) 2014-10-09
EP3257564A1 (en) 2017-12-20
LT3257564T (lt) 2019-04-10
EP3527274A1 (en) 2019-08-21
US20190023768A1 (en) 2019-01-24
ES2637423T5 (es) 2022-03-17
PL2773438T5 (pl) 2022-01-17
SI2773438T2 (sl) 2022-05-31
JP2022033774A (ja) 2022-03-02
PL3257564T3 (pl) 2019-06-28
HUE043755T2 (hu) 2019-09-30

Similar Documents

Publication Publication Date Title
BR112014010406A2 (pt) cromatografia de sobrecarga e eluto
BR112012029904A2 (pt) métodos de purificação de polipeptídeos
BR112015001618A2 (pt) composições fungicidas
BR112014016287A2 (pt) composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
AR087715A1 (es) Anticuerpos anti pcsk9 y usos de los mismos
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
BR112013020086A2 (pt) anticorpos que se ligam especificamente à alfa-toxina de staphylococcus aureus e métodos de utilização
CL2013003790A1 (es) Composicion de aglutinante para la aglomeracion de minerales finas y procedimiento de granulacion utilizando el mismo
BR112014011594A2 (pt) anticorpos anti-il-36r
PT2766380T (pt) Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
EA201491644A1 (ru) Фармацевтические композиции
MX2013003182A (es) Purificacion de anticuerpos por cromatografia de lecho movil simulada.
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
BR112014002884A2 (pt) composição para estimulação ovariana controlada
MX2015012812A (es) Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.
IN2013CN09704A (pt)
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
BR112014010174A2 (pt) uso de uma composição para a fabricação de um produto para melhorar a função executiva de um indivíduo e para tratar o mesmo
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112014009376A2 (pt) composições
BR112014001950A2 (pt) métodos e composições para controlar pragas de nemátodos
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
PH12014501891A1 (en) Substituted chroman compounds as calcium sensing receptor modulators
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
BR112015012708A2 (pt) anticorpos para bmp-6

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]